TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model

Bibliographic Details
Title: TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model
Authors: Fengzhen Chen, Yanying Xu, Yulong Chen, Shu Shan
Source: Cancer Medicine, Vol 9, Iss 10, Pp 3584-3591 (2020)
Publisher Information: Wiley, 2020.
Publication Year: 2020
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: immunosuppression, ovarian cancer, regulatory T cell, TIGIT, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Ovarian cancer (OC) is the fifth‐leading cause of cancer‐related death in women with a pathogenesis involving activation of regulatory T cells (Tregs). The T‐cell immunoglobulin and ITIM domain (TIGIT) is a well‐known immune checkpoint molecule that inhibits T‐cell responses. However, the role of TIGIT in OC is not comprehensively understood. In this study, we revealed crucial functions of TIGIT in the development and progression of OC. ID8 cells were used to establish a murine OC model. TIGIT expression was increased in immune cells of OC mice, particularly in CD4+ Tregs. Anti‐TIGIT monoclonal antibodies (mAb) were used to block the function of TIGIT in OC mice, and we found that the anti‐TIGIT treatment reduced the proportion of CD4+ Tregs, but did not affect CD4+ and CD8+ T cells or natural killer cells. Splenic CD4+ Tregs from OC mice were isolated after the anti‐TIGIT treatment, and their functioning was examined. Inhibition of TIGIT lowered the degree of immunosuppression induced by CD4+ Tregs. A survival curve suggested that anti‐TIGIT treatment can improve the survival rate of OC in mice. We conclude that TIGIT enhanced CD4+ Tregs response and mediated immunosuppression in the OC model. Our data suggest that inhibition of TIGIT is a potential therapeutic target in OC patients.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-7634
Relation: https://doaj.org/toc/2045-7634
DOI: 10.1002/cam4.2976
Access URL: https://doaj.org/article/cf66cbf9cc7f43ed94ffb114a71b5a76
Accession Number: edsdoj.f66cbf9cc7f43ed94ffb114a71b5a76
Database: Directory of Open Access Journals
More Details
ISSN:20457634
DOI:10.1002/cam4.2976
Published in:Cancer Medicine
Language:English